Normal Ranges of Thiopurine Methyltransferase Activity Do Not Affect Thioguanine Nucleotide Concentrations With Azathioprine Therapy in Inflammatory Bowel Disease. Issue 3 (11th July 2020)
- Record Type:
- Journal Article
- Title:
- Normal Ranges of Thiopurine Methyltransferase Activity Do Not Affect Thioguanine Nucleotide Concentrations With Azathioprine Therapy in Inflammatory Bowel Disease. Issue 3 (11th July 2020)
- Main Title:
- Normal Ranges of Thiopurine Methyltransferase Activity Do Not Affect Thioguanine Nucleotide Concentrations With Azathioprine Therapy in Inflammatory Bowel Disease
- Authors:
- Jonason, David E
Sievers, Tyson
Trocke, Lindsay
Abraham, James M
Vaughn, Byron P - Abstract:
- Abstract: Background: Thiopurine methyltransferase (TPMT) activity influences azathioprine conversion into active metabolite 6-thioguanine nucleotide (6-TGN). Low TPMT activity correlates with high 6-TGN and risk for myelosuppression. Conversely, normal-to-high TPMT activity may be associated with low 6-TGN and drug resistance, the so-called hypermetabolizers. Our aim was to identify the effect of normal-to-high TPMT activity on 6-TGN concentrations in an inflammatory bowel disease population. Methods: A retrospective chart review of patients aged ≥18 with inflammatory bowel disease, on azathioprine, with documented TPMT activity and 6-TGN concentration was performed. Correlations were evaluated via the Spearman rho correlation coefficient. Linear regression was used to determine the effect of TPMT activity on 6-TGN accounting for confounders. Relationships between TPMT activity, drug dose, and 6-TGN levels were defined via average causal mediation effects. Results: One hundred patients were included. No correlation was observed between TPMT activity, azathioprine dosing, and metabolite concentrations. Overall, 39% of the cohort had a therapeutic 6-TGN level of >230 pmol/8 × 10 8 red blood cells (RBCs). No patient under 1 mg/kg achieved a therapeutic 6-TGN level, whereas 42% of patients taking 2.5 mg/kg did. The median 6-TGN concentration was higher for those in remission (254 pmol/8 × 10 8 RBCs, interquartile range: 174, 309) versus those not in remission (177 pmol/8 × 10 8Abstract: Background: Thiopurine methyltransferase (TPMT) activity influences azathioprine conversion into active metabolite 6-thioguanine nucleotide (6-TGN). Low TPMT activity correlates with high 6-TGN and risk for myelosuppression. Conversely, normal-to-high TPMT activity may be associated with low 6-TGN and drug resistance, the so-called hypermetabolizers. Our aim was to identify the effect of normal-to-high TPMT activity on 6-TGN concentrations in an inflammatory bowel disease population. Methods: A retrospective chart review of patients aged ≥18 with inflammatory bowel disease, on azathioprine, with documented TPMT activity and 6-TGN concentration was performed. Correlations were evaluated via the Spearman rho correlation coefficient. Linear regression was used to determine the effect of TPMT activity on 6-TGN accounting for confounders. Relationships between TPMT activity, drug dose, and 6-TGN levels were defined via average causal mediation effects. Results: One hundred patients were included. No correlation was observed between TPMT activity, azathioprine dosing, and metabolite concentrations. Overall, 39% of the cohort had a therapeutic 6-TGN level of >230 pmol/8 × 10 8 red blood cells (RBCs). No patient under 1 mg/kg achieved a therapeutic 6-TGN level, whereas 42% of patients taking 2.5 mg/kg did. The median 6-TGN concentration was higher for those in remission (254 pmol/8 × 10 8 RBCs, interquartile range: 174, 309) versus those not in remission (177 pmol/8 × 10 8 RBCs, interquartile range: 94.3, 287.8), though not significantly ( P = 0.08). Smoking was the only clinical factor associated with 6-TGN level. On multivariate linear regression, only age, azathioprine dose, and obese body mass index were predictive of metabolite concentration. Conclusions: Variations within the normal range of TPMT activity do not affect 6-TGN concentration. Lay Summary: Thiopurine methyltransferase (TPMT) activity in the normal or high range does not affect 6-thioguanine nucleotide concentration in patients with inflammatory bowel disease treated with azathioprine. Providers should not make assumptions about 6-thioguanine nucleotide concentration based on normal TPMT activity. … (more)
- Is Part Of:
- Crohn's & colitis 360. Volume 2:Issue 3(2020)
- Journal:
- Crohn's & colitis 360
- Issue:
- Volume 2:Issue 3(2020)
- Issue Display:
- Volume 2, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 2
- Issue:
- 3
- Issue Sort Value:
- 2020-0002-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-07-11
- Subjects:
- therapeutic drug monitoring -- azathioprine -- inflammatory bowel disease -- thiopurine methyltransferase -- 6-thioguanine nucleotide
Crohn's disease -- Periodicals
Colitis -- Periodicals
616.344 - Journal URLs:
- http://www.oxfordjournals.org/ ↗
https://academic.oup.com/crohnscolitis360 ↗ - DOI:
- 10.1093/crocol/otaa058 ↗
- Languages:
- English
- ISSNs:
- 2631-827X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14852.xml